What is Kura Oncology's cash ratio?

Kura Oncology (KURA) reported cash ratio of 0.4× in Q1 2026.

How has Kura Oncology's cash ratio changed year-over-year?

Kura Oncology's cash ratio decreased by 32.6% year-over-year, from 0.6× to 0.4×.

What is the long-term trend for Kura Oncology's cash ratio?

Over 5 years (2020 to 2025), Kura Oncology's cash ratio has grown at a -36.7% compound annual growth rate (CAGR), from 12.5× to 1.3×.

What does cash ratio mean?

Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.

Kura Oncology KURA Cash ratio

Cash ratio at other companies

Johnson & JohnsonJNJ

0.4×-0.3×

AmgenAMGN

0×0.0×

ExelixisEXEL

0.6×+0.1×

Syndax PharmaceuticalsSNDX

1.5×-0.1×

AbbVieABBV

0.2×+0.1×

Corvus PharmaceuticalsCRVS

3.3×+2.8×

Other financials

Income statement

See full

Revenue$18.3M+29.5%

Gross profit$18.0M—

Operating income-$78.8M-21.8%

Net income-$73.3M-27.7%

EPS (diluted)-$0.83-25.8%

Balance sheet

See full

Cash & equivalents$39.1M-23.8%

Total debt$24.3M+25.4%

Total equity$107.9M-70.4%

Total assets$652.6M-12.3%

Cash flow

See full

Operating cash flow-$85.9M-19.4%

CapEx$128.0K-56.2%

Free cash flow-$86.0M-19.1%

Valuation

See full

Market cap$942.78M+81.6%

Enterprise value$927.97M+90.7%

P/S13.2×+3.6×

Profitability

See full

Operating margin-443.5%+103pp

Net margin-411.2%+125pp

FCF margin130.6%+74.1pp

Returns & leverage

See full

Return on equity-124.7%-252pp

Debt / equity0.2×+0.2×

Current ratio6.1×-1.9×

Where this comes from

Calculated from Kura Oncology’s reported figures.

cash and equivalents/total current liabilities=0.4×

Based on the most recent quarter.

The official record: Kura Oncology’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kura Oncology's cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Kura Oncology's cash ratio?: Kura Oncology (KURA) reported cash ratio of 0.4× in Q1 2026.
How has Kura Oncology's cash ratio changed year-over-year?: Kura Oncology's cash ratio decreased by 32.6% year-over-year, from 0.6× to 0.4×.
What is the long-term trend for Kura Oncology's cash ratio?: Over 5 years (2020 to 2025), Kura Oncology's cash ratio has grown at a -36.7% compound annual growth rate (CAGR), from 12.5× to 1.3×.
What does cash ratio mean?: Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.